Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.43 |
| ▸ | PDE4A | P27815 | 7/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.42 |
| ▸ | GLRB | P48167 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20064128 | 0.94 | GLRA3 (0.42) | POLBPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL21222564 | 0.94 | GLRA3 (0.42) | POLBPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL21222626 | 0.88 | PDE4D (0.43) | PDE4DPDE4BPDE4APDE4CSLC6A2 | |
| SCHEMBL20064124 | 0.88 | PDE4D (0.43) | PDE4DPDE4BPDE4APDE4CSLC6A2 | |
| SCHEMBL21222421 | 0.87 | PDE4A (0.52) | POLBPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL21227929 | 0.87 | SMN1; SMN2 (0.52) | POLBPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL21222609 | 0.87 | FFAR1 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21227833 | 0.87 | PDE4D (0.43) | POLBPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL21222420 | 0.87 | PDE4A (0.52) | POLBPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL21222608 | 0.87 | FFAR1 (0.41) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053234-B2 | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors | HPGDS, PTGDR, PTGER1 | POLB 1254/4885PDE4D 246/4885PDE4B 457/4885 |
| US-20190241554-A1 | 1,3 DI-SUBSTITUTED CYCLOBUTANE OR AZETIDINE DERIVATIVES AS HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE INHIBITORS | HPGDS, PTGDR, PTGER1 | POLB 1254/4885PDE4D 246/4885PDE4B 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.